Neurological manifestations of the antiphospholipid syndrome: Risk assessments and evidence-based medicine

International Journal of Clinical Practice

Volumn 61, Issue 9, 2007, Pages 1561-1568

  Muscal, E ^a   Brey, R L ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE RECEPTOR BLOCKING AGENT; ANTIMALARIAL AGENT; ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PHOSPHOLIPID BINDING PROTEIN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; BIOCHEMISTRY; CARDIOVASCULAR RISK; CELL ACTIVATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENDOTHELIUM CELL; EVIDENCE BASED MEDICINE; HUMAN; LABORATORY DIAGNOSIS; LIFESTYLE MODIFICATION; MORBIDITY; NEUROLOGIC DISEASE; PATHOGENESIS; PEDIATRICS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOCYTE; THROMBOPHILIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CEREBROVASCULAR ACCIDENT; HUMANS; LUPUS COAGULATION INHIBITOR; RISK ASSESSMENT; RISK FACTORS; VENOUS THROMBOSIS; WARFARIN;

EID: 34547729701     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01478.x     Document Type: Review

References (40)

1. Bertolaccini ML, Khamashta MA, Hughes GRV. Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol 2005 1 : 40 6.
2. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002 346 : 752 63.
3. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006 4 : 295 306.
4. Lockshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Med 2003 349 : 1177 9.
5. Hanly JG. Antiphospholipid syndrome: an overview. CMAJ 2003 168 : 1675 82.
6. Lim W, Crowther MA, Eikelboom JW. Management of the antiphospholipid antibody syndrome: a systemic review. JAMA 2006 295 : 1050 7.
7. Kamat AV, D'Cruz DP, Hunt BJ. Managing antiphospholipid antibodies and antiphospholipid syndrome in children. Haematologica 2006 91 : 1674 80.
8. Pierangelli SS, Chen PP, González EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006 13 : 366 75.
9. Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002 61 : 46 50.
10. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004 10 : 1222 6.
11. Caronti B, Calderaro C, Alessandri C et al. Serum anti-β2- glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun 1998 11 : 425 9.
12. Katzav A, Chapman J, Shoenfeld Y. CNS dysfunction in the antiphospholipid syndrome. Lupus 2003 12 : 903 7.
13. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardization committee of the ISTH. Thromb Haemost 1995 74 : 1185 90.
14. Galli M, Luciani D, Bertolini G et al. Lupus anticoagulants are stronger risk factors for thrombosis than antocardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2005 101 : 1827 32.
15. Sanna G, Bertolaccini ML, Cuadrado MJ et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 2003 42 : 200 13.
16. Brey RL. Management of the neurological manifestations of APS-what do the trials tell us? Thromb Res 2004 114 : 489 99.
17. Janhardan V, Wolf PA, Kase CS et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attacks: the Framingham cohort and offspring study. Stroke 2004 35 : 736 41.
18. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003 82 : 299 308.
19. Cimaz R, Descloux E. Pediatric antiphospholipid syndrome. Rheum Dis Clin North Am 2006 32 : 553 73.
20. Angelini L, Ravelli A, Caporali R et al. High prevalence of antiphospholipid antibodies in children with idiopathic cerebral ischemia. Pediatrics 1994 94 : 500 3.
21. Lanthier S, Kirkham FJ, Mitchell LG et al. Increased anticardiolipin antibody IgG titers do not predict recurrent stroke or TIA in children. Neurology 2004 62 : 194 200.
22. Berkun Y, Padeh S, Barash J et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum 2006 55 : 850 5.
23. Chapman J, Cohen-Armon M, Shoenfeld Y et al. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999 8 : 127 33.
24. Menon S, Jameson-Shortall E, Newman SP et al. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999 42 : 735 41.
25. Hanly JG, Hong C, Smith S et al. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999 42 : 728 34.
26. Jacobson MW, Rapport LJ, Keenan PA et al. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol 1999 21 : 251 64.
27. Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004 126 (3 Suppl. 401S 28S.
28. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992 117 : 303 8.
29. Khamashta MA, Cudardo MJ, Mujic F et al. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995 332 : 993 7.
30. Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003 349 : 1133 8.
31. Finazzi G, Marchioli R, Brancaccio V et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005 3 : 848 53.
32. The APASS Writing Committee. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004 291 : 576 84.
33. Khamashta MA, Hunt BJ. Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. J Thromb Haemost 2005 3 : 844 5.
34. Ruiz-Irastorza G, Khamashta MA. Stroke and antiphospholipid syndrome: the treatment debate. Rheumatology 2005 44 : 971 4.
35. Alarcon-Segovia D, Boffa MC, Branch W et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 2003 12 : 499 503.
36. Toloza SMA, Uribe AG, McGwin G et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004 50 : 3947 57.
37. Akimoto T. Risk factors for recurrent thrombosis: prospective study of a cohort of Japanese systemic lupus erythematosus. Angiology 2005 56 : 601 9.
38. Roldan CA, Gelgand EA, Qualls CR et al. Valvular heart disease as a cause of cerebrovascular disease in patients with systemic lupus erythematosus. Am J Cardiol 2005 95 : 1441 7.
39. Krause I, Lev S, Fraser A et al. Close association between valvular heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005 64 : 1490 3.
40. Roubey RAS. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials and tribulations. Arthritis Rheum 2003 48 : 3004 8.